JP6124986B2 - 拡張期心不全を処置するための増殖分化因子（ｇｄｆ） - Google Patents

拡張期心不全を処置するための増殖分化因子（ｇｄｆ） Download PDF

Info

Publication number
JP6124986B2
JP6124986B2 JP2015501721A JP2015501721A JP6124986B2 JP 6124986 B2 JP6124986 B2 JP 6124986B2 JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015501721 A JP2015501721 A JP 2015501721A JP 6124986 B2 JP6124986 B2 JP 6124986B2
Authority
JP
Japan
Prior art keywords
gdf11
mice
polypeptide
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512387A (ja
JP2015512387A5 (enExample
Inventor
リチャード ティー． リー
リチャード ティー． リー
フランチェスコ ロフレド
フランチェスコ ロフレド
ジェイムズ パンコースト
ジェイムズ パンコースト
マシュー スタインハウザー
マシュー スタインハウザー
エイミー ウエイジャーズ
エイミー ウエイジャーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2015512387A publication Critical patent/JP2015512387A/ja
Publication of JP2015512387A5 publication Critical patent/JP2015512387A5/ja
Application granted granted Critical
Publication of JP6124986B2 publication Critical patent/JP6124986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015501721A 2012-03-19 2013-03-11 拡張期心不全を処置するための増殖分化因子（ｇｄｆ） Active JP6124986B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261612550P 2012-03-19 2012-03-19
US61/612,550 2012-03-19
US201261649962P 2012-05-22 2012-05-22
US61/649,962 2012-05-22
PCT/US2013/030140 WO2013142114A1 (en) 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure

Publications (3)

Publication Number Publication Date
JP2015512387A JP2015512387A (ja) 2015-04-27
JP2015512387A5 JP2015512387A5 (enExample) 2016-04-07
JP6124986B2 true JP6124986B2 (ja) 2017-05-10

Family

ID=49223184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501721A Active JP6124986B2 (ja) 2012-03-19 2013-03-11 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）

Country Status (6)

Country Link
US (1) US9434779B2 (enExample)
EP (1) EP2828289B1 (enExample)
JP (1) JP6124986B2 (enExample)
CA (1) CA2901394A1 (enExample)
ES (1) ES2779698T3 (enExample)
WO (1) WO2013142114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
JP2016518357A (ja) * 2013-04-08 2016-06-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨格筋幹細胞を若返らせる方法および組成物
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
WO2015073396A1 (en) * 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
EP3142680A4 (en) * 2014-05-16 2018-05-23 Intermune, Inc. Lpa-associated protein and rna expression
WO2016049662A1 (en) * 2014-09-23 2016-03-31 President And Fellows Of Harvard College Methods and compositions for treating age-related disorders
AU2015353767B2 (en) 2014-11-24 2021-09-09 Somalogic Operating Co., Inc. Nucleic acid compounds for binding growth differentiation factor 11
WO2017115789A1 (ja) 2015-12-28 2017-07-06 国立研究開発法人理化学研究所 加齢による生理機能の低下を回復または改善する組成物
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
WO2019144053A1 (en) * 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof
US20200222459A1 (en) * 2019-01-16 2020-07-16 Melvin Barnes System, Method and Compositions for Treating Age-Related Illnesses and Conditions
JP2022001603A (ja) * 2021-10-14 2022-01-06 功 加治佐 自分由来ｉＰＳ若い血液応用ＧＤＦ１１分子コーティング若返り経口不老不死薬９
CN114989310B (zh) * 2022-06-20 2024-11-19 深圳先进技术研究院 一种嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及应用
CN115212299A (zh) * 2022-06-21 2022-10-21 深圳先进技术研究院 Car-t和car-m联用在制备抗肿瘤药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
PT698094E (pt) * 1993-05-12 2004-05-31 Inst Genetics Llc Composicoes de bmp-11
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP0985149A1 (en) 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
WO2004073633A2 (en) * 2003-02-14 2004-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating the development of stem cells
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007142818A2 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP3141905B1 (en) 2008-03-27 2019-03-06 Promega Corporation Protein labeling with cyanobenzothiazole conjugates

Also Published As

Publication number Publication date
JP2015512387A (ja) 2015-04-27
US20150045297A1 (en) 2015-02-12
EP2828289B1 (en) 2020-02-26
US9434779B2 (en) 2016-09-06
EP2828289A1 (en) 2015-01-28
CA2901394A1 (en) 2013-09-26
ES2779698T3 (es) 2020-08-18
EP2828289A4 (en) 2016-01-06
WO2013142114A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
JP6124986B2 (ja) 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）
JP2022101593A (ja) ミオスタチン阻害剤の使用および併用療法
US11612639B2 (en) Methods and compositions for rejuvenating skeletal muscle stem cells
US7947280B2 (en) Apelin and uses thereof
US11725033B2 (en) GDF11 variants and uses thereof
US20160264657A1 (en) Growth differentiation factor (gdf) for treatment of diastolic heart failure
EP3007719B1 (en) Methods and compositions for increasing neurogenesis and angiogenesis
WO2016118859A1 (en) Compositions and methods for selectively depleting senescent cells comprising flip
JP2012518630A (ja) 挫瘡およびその他の状態を治療するためのビスファチン治療薬
US20200306244A1 (en) Wnt inhibitors for use in the treatment of fibrosis
JP6198742B2 (ja) 肺高血圧症
JP7697879B2 (ja) 筋肉減少症又は廃用性萎縮症の治療のための組成物
US20200031873A1 (en) Repurposing cell penetrating peptides and their novel derivatives and iopromide and iodo-aryl carbonates for treatment of senescence-related diseases and disorders
US20220062299A1 (en) Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP2019516778A (ja) 虚血障害または虚血再灌流障害の予防および／または治療
US8506965B2 (en) R-RAS activity in vascular regulation
JP5197887B2 (ja) イミュノグロブリン結合能を有するペプチド
WO2024112749A1 (en) Methods of treating heart failure
WO2024137306A1 (en) Compositions and methods for treating diabetic cardiomyopathy
WO2021032955A1 (en) Treatment
KR20190060642A (ko) 심부전의 예방 또는 치료용 의약
Breitbart et al. Articles in PresS. Am J Physiol Heart Circ Physiol (March 18, 2011). doi: 10.1152/ajpheart. 00200.2011

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150324

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170404

R150 Certificate of patent or registration of utility model

Ref document number: 6124986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250